Literature DB >> 13108975

Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.

T F YU, J H SIROTA, A B GUTMAN.   

Abstract

Entities:  

Keywords:  ANALGESICS/effects; GOUT/therapy; KIDNEYS/physiology; URIC ACID/metabolism

Mesh：

Substances：

Year:  1953        PMID： 13108975      PMCID： PMC438451          DOI： 10.1172/JCI102836

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  8 in total

1.  Effect of butazolidine on the excretion of water and electrolytes.

Authors:  J GREEN; P O WILLIAMS
Journal:  Lancet       Date:  1953-03-21       Impact factor: 79.321

2.  [Effect of irgapyrine and butazolidine on modifications of electolytic metabolism and glomerular and tubular functions].

Authors:  P DUPONT; A DUCKERT-MAULBETSCH; J FABRE
Journal:  Helv Med Acta       Date:  1952-12

3.  Current principles of management in gout.

Authors:  A B GUTMAN; T F YU
Journal:  Am J Med       Date:  1952-12       Impact factor: 4.965

4.  [The effect of irgapyrin on renal functions].

Authors:  E BERTHOUD
Journal:  Helv Med Acta       Date:  1952-10

5.  Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects.

Authors:  J H SIROTA; T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1952-07       Impact factor: 14.808

6.  Phenylbutazone (butazolidin) in rheumatoid arthritis and gout.

Authors:  W C KUZELL; R W SCHAFFARZICK; B BROWN; E A MANKLE
Journal:  J Am Med Assoc       Date:  1952-06-21

7.  The effect of butazolidin (phenylbutazone) on water and electrolyte excretion.

Authors:  E L WILKINSON; H BROWN
Journal:  Am J Med Sci       Date:  1953-02       Impact factor: 2.378

8.  Clinical studies of phenylbutazone (butazolidin) and butapyrin (irgapyrin) in rheumatoid arthritis, rheumatoid spondylitis, and gout.

Authors:  E G KIDD; K C BOYCE; R H FREYBERG
Journal:  Ann Rheum Dis       Date:  1953-03       Impact factor: 19.103
  8 in total
  11 in total

1.  Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  The uricosuria and orotic aciduria induced by 6-azauridine.

Authors:  H J FALLON; E FREI; J BLOCK; J E SEEGMILLER
Journal:  J Clin Invest       Date:  1961-10       Impact factor: 14.808

3.  Value of uricosuric agents and in particular of G. 28 315 in gout.

Authors:  G D KERSLEY; E R COOK; D C TOVEY
Journal:  Ann Rheum Dis       Date:  1958-09       Impact factor: 19.103

4.  Overproduction of uric acid as the cause of hyperuricemia in primary gout.

Authors:  J B WYNGAARDEN
Journal:  J Clin Invest       Date:  1957-10       Impact factor: 14.808

5.  Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents.

Authors:  A B GUTMAN; T F YU
Journal:  Bull N Y Acad Med       Date:  1958-05

6.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

7.  Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.

Authors:  T F YU; B C PATON; T CHENKIN; J J BURNS; B B BRODIE; A B GUTMAN
Journal:  J Clin Invest       Date:  1956-04       Impact factor: 14.808

8.  Recent advances in rheumatic diseases.

Authors:  E W BOLAND
Journal:  Calif Med       Date:  1955-02

9.  The effect of phenylbutazone on uric acid metabolism in two normal subjects.

Authors:  J B WYNGAARDEN
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

10.  The estimation of butazolidin in blood.

Authors:  D G MOSS
Journal:  J Clin Pathol       Date:  1954-11       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.